Sanofi Invests in Atalanta's $97 Million Series B Round
Deal News | Jan 31, 2025 | Ropes & Gray
Sanofi, a leading healthcare company, has co-led a $97 million Series B financing in Atalanta Therapeutics, a biotechnology firm specializing in RNA interference for neurological diseases. The financing round was co-led by EQT Life Sciences and Sanofi Ventures, with participation from new investors such as RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, and GHR Foundation, along with existing investor F-Prime Capital. Ropes & Gray, a prominent law firm, represented Sanofi in this transaction, with a team comprising venture capital and emerging companies associates Daniel Freshman and Derek Mubiru, partner Rajarshi Banerjee, and litigation & enforcement partner Brendan Hanifin.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United States – The involvement of Sanofi, which has operations in the U.S., and law firm Ropes & Gray, headquartered in Boston, indicates a significant U.S. presence.
Industry
- Biotechnology – The article discusses a funding round for Atalanta Therapeutics, a biotech company innovating in RNA interference for neurological diseases.
- Pharmaceuticals – Sanofi, a global healthcare leader and one of the co-lead investors in Atalanta's financing round, operates in this industry.
- Venture Capital – The inclusion of various venture funds such as Sanofi Ventures and Novartis Venture Fund highlights this industry's involvement in funding biotech innovations.
Financials
- 97,000,000 – The amount raised in Atalanta Therapeutics' Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sanofi | Co-Lead Investor | Company | A global healthcare leader involved in the life sciences sector. |
| Atalanta Therapeutics | Target Company | Company | A biotechnology firm pioneering RNA interference treatments for neurological diseases. |
| Ropes & Gray | Legal Advisor | Company | A law firm that represented Sanofi in the investment transaction. |
| EQT Life Sciences | Co-Lead Investor | Company | An investment firm specializing in the life sciences sector. |
| Sanofi Ventures | Investor | Company | An investment vehicle of Sanofi, focused on innovative healthcare ventures. |
| RiverVest Venture Partners | Investor | Company | A venture capital firm that invests in early-stage life sciences companies. |
| abrdn Inc. | Investor | Company | Manages investment funds, involved in this financing round. |
| Novartis Venture Fund | Investor | Company | The venture arm of Novartis, focused on life science companies. |
| Pictet Alternative Advisors | Investor | Company | An investment management firm involved in the financing. |
| Mirae Asset Financial Group | Investor | Company | A global financial group with investments in various sectors. |
| GHR Foundation | Investor | Charity | A foundation involved in funding innovative ventures. |
| F-Prime Capital | Investor | Company | An existing investor in Atalanta Therapeutics. |
| Daniel Freshman | Venture Capital and Emerging Companies Associate | Person | An associate at Ropes & Gray involved in the transaction. |
| Derek Mubiru | Venture Capital and Emerging Companies Associate | Person | An associate at Ropes & Gray involved in the transaction. |
| Rajarshi Banerjee | Venture Capital and Emerging Companies Partner | Person | A partner at Ropes & Gray involved in the transaction. |
| Brendan Hanifin | Litigation & Enforcement Partner | Person | A partner at Ropes & Gray involved in the transaction. |